Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 67 articles: HTML format

Single Articles

May 2023
1. KRISTIANSEN MF, Mikkelsen RM, Kristiansdottir T, Andorsdottir G, et al
   Cancer survival in the Faroe Islands over the last 50 years compared to the other Nordic countries.
   Int J Cancer. 2023;152:2090-2098.
   PubMed     Abstract available
   
   
   April 2023
2. VAN STEENHOVEN JEC, van Maaren MC, Verreck EEF, Schipper RJ, et al
   Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: Innovative hospitals are early adopters of a de-escalating approach.
   Int J Cancer. 2023;152:1378-1387.
   PubMed     Abstract available
   
   
   
3. WAGENER R, Walter C, Auer F, Alzoubi D, et al
   The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients.
   Int J Cancer. 2023;152:1388-1398.
   PubMed     Abstract available
   
   
   March 2023
4. QIN Z, Li J, Tam B, Sinha S, et al
   Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population.
   Int J Cancer. 2023;152:1159-1173.
   PubMed     Abstract available
   
   
   
5. CARDOSO R, Hoffmeister M, Brenner H
   Breast cancer screening programmes and self-reported mammography use in European countries.
   Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34494.
   PubMed     Abstract available
   
   
   February 2023
6. CHANG VC, Rhee J, Berndt SI, Moore SC, et al
   Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
   Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34487.
   PubMed     Abstract available
   
   
   
7. LIU S, van Dinther M, Hagenaars SC, Gu Y, et al
   Differential Optineurin expression controls TGFbeta signaling and is a key determinant for metastasis of triple negative breast cancer.
   Int J Cancer. 2023 Feb 23. doi: 10.1002/ijc.34483.
   PubMed     Abstract available
   
   
   
8. XIA C, Yu XQ, Chen W
   Measuring population-level cure patterns for cancer patients in the United States.
   Int J Cancer. 2023;152:738-748.
   PubMed     Abstract available
   
   
   
9. JIA G, Yang Y, Ping J, Xu S, et al
   Identification of target proteins for breast cancer genetic risk loci and blood risk biomarkers in a large study by integrating genomic and proteomic data.
   Int J Cancer. 2023 Feb 13. doi: 10.1002/ijc.34472.
   PubMed     Abstract available
   
   
   
10. GETU MA, Chen C, Addissie A, Seife E, et al
    The effect of cognitive behavioural therapy integrated with activity pacing on cancer-related fatigue, depression and quality of life among patients with breast cancer undergoing chemotherapy in Ethiopia: a randomised clinical trial.
    Int J Cancer. 2023 Feb 6. doi: 10.1002/ijc.34452.
    PubMed     Abstract available
    
    
    January 2023
11. GONZALEZ-CALLEJO P, Gener P, Diaz-Riascos ZV, Conti S, et al
    Extracellular vesicles secreted by triple negative breast cancer stem cells trigger pre-metastatic niche remodeling and metastatic growth in the lungs.
    Int J Cancer. 2023 Jan 27. doi: 10.1002/ijc.34447.
    PubMed     Abstract available
    
    
    
12. XU B, Ma F, Wang T, Wang S, et al
    A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments.
    Int J Cancer. 2023 Jan 9. doi: 10.1002/ijc.34424.
    PubMed     Abstract available
    
    
    
13. KAR A, Medatwal N, Rajput K, Mandal S, et al
    Unique Sphingolipid Signature Identifies Luminal and Triple-Negative Breast Cancer Subtypes.
    Int J Cancer. 2023 Jan 5. doi: 10.1002/ijc.34423.
    PubMed     Abstract available
    
    
    December 2022
14. BOUCHERON P, Anele A, Offiah AU, Zietsman A, et al
    Reproductive history and breast cancer survival: findings from the African Breast Cancer - Disparities in Outcomes cohort and implications of Africa's fertility transition on breast cancer prognosis.
    Int J Cancer. 2022 Dec 22. doi: 10.1002/ijc.34411.
    PubMed     Abstract available
    
    
    November 2022
15. HEY J, Halperin C, Hartmann M, Mayer S, et al
    DNA methylation landscape of tumor-associated macrophages reveals pathways, transcription factors, and prognostic value relevant to triple-negative breast cancer patients.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34364.
    PubMed     Abstract available
    
    
    
16. LIN M, Jin Y, Lv H, Hu X, et al
    Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34365.
    PubMed     Abstract available
    
    
    
17. ARMAROLI P, Frigerio A, Correale L, Ponti A, et al
    A randomised controlled trial of digital breast tomosynthesis vs digital mammography as primary screening tests: Screening results over subsequent episodes of the Proteus Donna study.
    Int J Cancer. 2022;151:1778-1790.
    PubMed     Abstract available
    
    
    
18. ALCARAZ LB, Mallavialle A, Mollevi C, Boissiere-Michot F, et al
    SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34345.
    PubMed     Abstract available
    
    
    
19. CAIRAT M, Pottegard A, Olesen M, Dossus L, et al
    Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34343.
    PubMed     Abstract available
    
    
    October 2022
20. MANOOCHEHRI M, Borhani N, Gerhauser C, Assenov Y, et al
    DNA methylation biomarkers for non-invasive detection of triple negative breast cancer using liquid biopsy.
    Int J Cancer. 2022 Oct 28. doi: 10.1002/ijc.34337.
    PubMed     Abstract available
    
    
    
21. CARIOLOU M, Abar L, Aune D, Balducci K, et al
    Postdiagnosis recreational physical activity and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34324.
    PubMed     Abstract available
    
    
    
22. BECERRA-TOMAS N, Balducci K, Abar L, Aune D, et al
    Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34321.
    PubMed     Abstract available
    
    
    
23. TSILIDIS KK, Cariolou M, Becerra-Tomas N, Balducci K, et al
    Postdiagnosis body fatness, recreational physical activity, dietary factors and breast cancer prognosis: Global Cancer Update Programme (CUP Global) summary of evidence grading.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34320.
    PubMed     Abstract available
    
    
    
24. CHAN DSM, Vieira R, Abar L, Aune D, et al
    Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34322.
    PubMed     Abstract available
    
    
    
25. LYNGE E, Vjeborg I, Lillholm M, Nielsen M, et al
    Breast Density and Risk of Breast Cancer.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34316.
    PubMed     Abstract available
    
    
    
26. BAHAR-SHANY K, Barnabas GD, Deutsch L, Deutsch N, et al
    Proteomic Signature for Detection of High Grade Ovarian Cancer in germline BRCA mutation carriers.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34318.
    PubMed     Abstract available
    
    
    September 2022
27. KANKURI-TAMMILEHTO M, Tervasmaki A, Kraatari-Tiri M, Rahikkala E, et al
    ATM c.7570G>C is a high-risk allele for breast cancer.
    Int J Cancer. 2022 Sep 26. doi: 10.1002/ijc.34305.
    PubMed     Abstract available
    
    
    
28. MAILLIEZ A, D'Hondt V, Lusque A, Caron O, et al
    Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
    Int J Cancer. 2022 Sep 26. doi: 10.1002/ijc.34304.
    PubMed     Abstract available
    
    
    
29. WU J, Tan X
    The role of MTNR1B polymorphism on circadian rhythm-related cancer: A UK Biobank cohort study.
    Int J Cancer. 2022;151:888-896.
    PubMed     Abstract available
    
    
    August 2022
30. LOK SW, De Boer R, Baron-Hay S, Button P, et al
    Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA).
    Int J Cancer. 2022 Aug 16. doi: 10.1002/ijc.34245.
    PubMed     Abstract available
    
    
    
31. KREGTING LM, Sankatsing VDV, Heijnsdijk EAM, de Koning HJ, et al
    Reply to: Comments on "Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modeled strategies".
    Int J Cancer. 2022;151:651-652.
    PubMed    
    
    
    
32. BRAILLON A
    Comments on "Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modeled strategies".
    Int J Cancer. 2022;151:649-650.
    PubMed    
    
    
    
33. PEILA R, Lane DS, Shadyab AH, Saquib N, et al
    Healthy lifestyle index and the risk of ductal carcinoma in situ of the breast in the Women's Health Initiative.
    Int J Cancer. 2022;151:526-538.
    PubMed     Abstract available
    
    
    July 2022
34. MATTA M, Deubler E, Chajes V, Vozar B, et al
    Circulating plasma phospholipid fatty acid levels and breast cancer risk in the Cancer Prevention Study-II Nutrition Cohort.
    Int J Cancer. 2022 Jul 18. doi: 10.1002/ijc.34216.
    PubMed     Abstract available
    
    
    
35. KREGTING LM, Sankatsing VDV, Heijnsdijk EAM, de Koning HJ, et al
    Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies.
    Int J Cancer. 2022;151:287-296.
    PubMed     Abstract available
    
    
    
36. BASSETT JK, MacInnis RJ, Yang Y, Hodge AM, et al
    Alcohol intake trajectories during the life course and risk of alcohol-related cancer: A prospective cohort study.
    Int J Cancer. 2022;151:56-66.
    PubMed     Abstract available
    
    
    June 2022
37. KARAVASILOGLOU N, Pestoni G, Kuhn T, Rohrmann S, et al
    Adherence to cancer prevention recommendations and risk of breast cancer in situ in the United Kingdom Biobank.
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34183.
    PubMed     Abstract available
    
    
    
38. DESCHASAUX-TANGUY M, Barrubes Pinol L, Sellem L, Debras C, et al
    Dairy product consumption and risk of cancer: A short report from the NutriNet-Sante prospective cohort study.
    Int J Cancer. 2022;150:1978-1986.
    PubMed     Abstract available
    
    
    
39. RATOSA I, Dobnikar N, Bottosso M, Dieci MV, et al
    Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: real-world data from a multicentric European cohort.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34135.
    PubMed     Abstract available
    
    
    
40. WU Z, Byrd DA, Wan Y, Ansong D, et al
    The oral microbiome and breast cancer and non-malignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34145.
    PubMed     Abstract available
    
    
    
41. HENNINGSEN MB, McWhan K, Dam VS, Mele M, et al
    Amplified Ca(2+) dynamics and accelerated cell proliferation in breast cancer tissue during purinergic stimulation.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34147.
    PubMed     Abstract available
    
    
    April 2022
42. ALLALI S, Carton M, Sarrade T, Querel O, et al
    CANTO-RT: Skin toxicities evaluation of a multicenter large prospective cohort of irradiated patients for early-stage breast cancer.
    Int J Cancer. 2022 Apr 30. doi: 10.1002/ijc.34057.
    PubMed     Abstract available
    
    
    
43. TRAN TXM, Kim S, Song H, Park B, et al
    Mammographic Breast Density, Body Mass Index, and Risk of Breast Cancer in Korean Women Aged 75 Years and Older.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34038.
    PubMed     Abstract available
    
    
    
44. BOUWER NI, Steenbruggen TG, Rier HN, Kitzen JJ, et al
    The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
    Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34024.
    PubMed     Abstract available
    
    
    
45. CHEN F, Wen W, Long J, Shu X, et al
    Mendelian randomization analyses of 23 known and suspected risk factors and biomarkers for breast cancer overall and by molecular subtypes.
    Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34026.
    PubMed     Abstract available
    
    
    
46. XIU M, Zhang P, Wang X, Fan Y, et al
    Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant versus standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: a prospective cohort study with propensity-matched analysis.
    Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34022.
    PubMed     Abstract available
    
    
    
47. RASHID MU, Muhammad N, Naeemi H, Shehzad U, et al
    Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34016.
    PubMed     Abstract available
    
    
    March 2022
48. XIE Y, Zhang Y, Xie K, Zhong X, et al
    Impact of time to initiation of postoperative radiotherapy after neoadjuvant chemotherapy on the prognosis of breast cancer: a retrospective cohort study in China.
    Int J Cancer. 2022 Mar 25. doi: 10.1002/ijc.34003.
    PubMed     Abstract available
    
    
    
49. WATT GP, Knight JA, Nguyen TL, Reiner AS, et al
    Association of contralateral breast cancer risk with mammographic density defined at higher-than-conventional intensity thresholds.
    Int J Cancer. 2022 Mar 22. doi: 10.1002/ijc.34001.
    PubMed     Abstract available
    
    
    February 2022
50. AYENI OA, O'Neil DS, Pumpalova YS, Chen WC, et al
    Impact of HIV infection on Survival among Women with Stage I-III Breast Cancer: Results from the South African Breast Cancer and HIV Outcomes Study.
    Int J Cancer. 2022 Feb 26. doi: 10.1002/ijc.33981.
    PubMed     Abstract available
    
    
    
51. HAFSTAETH V, Sokilde R, Hakkinen J, Larsson M, et al
    Regulatory networks and 5' partner usage of miRNA host gene fusions in breast cancer.
    Int J Cancer. 2022 Feb 19. doi: 10.1002/ijc.33972.
    PubMed     Abstract available
    
    
    
52. JOHANSSON A, Yiu-Lin Yu N, Iftimi A, Tobin NP, et al
    Clinical and Molecular Characteristics of ER-Positive Ultralow Risk Breast Cancer Tumors Identified by the 70-Gene Signature.
    Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33969.
    PubMed     Abstract available
    
    
    
53. HA MJ, Raghavendra AS, Kettner NM, Qiao W, et al
    Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting-a large institutional study.
    Int J Cancer. 2022 Feb 8. doi: 10.1002/ijc.33959.
    PubMed     Abstract available
    
    
    
54. FLUGELMAN AA, Burton A, Keinan-Boker L, Stein N, et al
    Correlation between cumulative mammographic density and age - specific incidence of breast cancer: a bi-ethnic study in israel.
    Int J Cancer. 2022 Feb 6. doi: 10.1002/ijc.33957.
    PubMed     Abstract available
    
    
    January 2022
55. SWERDLOW AJ, Bruce C, Cooke R, Coulson P, et al
    Risk of breast cancer in men in relation to weight change: a national case-control study in England and Wales.
    Int J Cancer. 2022 Jan 20. doi: 10.1002/ijc.33938.
    PubMed     Abstract available
    
    
    
56. MAILLIEZ A, Pigny P, Bogart E, Keller L, et al
    Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients.
    Int J Cancer. 2022 Jan 17. doi: 10.1002/ijc.33933.
    PubMed     Abstract available
    
    
    
57. GOTTSCHAU M, Bens A, Friis S, Cronin-Fenton D, et al
    Use of beta-blockers and risk of contralateral breast cancer.
    Int J Cancer. 2022 Jan 5. doi: 10.1002/ijc.33923.
    PubMed     Abstract available
    
    
    December 2021
58. ZHOU W, Jiang Y, Xu Y, Wang Y, et al
    Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: a propensity-score matched cohort study.
    Int J Cancer. 2021 Dec 26. doi: 10.1002/ijc.33919.
    PubMed     Abstract available
    
    
    
59. ABASCAL MF, Elia A, Alvarez M, Pataccini G, et al
    Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.
    Int J Cancer. 2021 Dec 22. doi: 10.1002/ijc.33913.
    PubMed     Abstract available
    
    
    
60. WEGE AK, Rom-Jurek EM, Jank P, Denkert C, et al
    mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease.
    Int J Cancer. 2021 Dec 20. doi: 10.1002/ijc.33911.
    PubMed     Abstract available
    
    
    
61. PARK B
    Changes in weight and waist circumference during menopausal transition and postmenopausal breast cancer risk.
    Int J Cancer. 2021 Dec 18. doi: 10.1002/ijc.33906.
    PubMed     Abstract available
    
    
    November 2021
62. LOAP P, Loirat D, Berger F, Cao K, et al
    Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial.
    Int J Cancer. 2021;149:1828-1832.
    PubMed     Abstract available
    
    
    
63. KIM DS, Ahn HS, Kim HJ
    Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database.
    Int J Cancer. 2021 Nov 9. doi: 10.1002/ijc.33869.
    PubMed     Abstract available
    
    
    October 2021
64. WANG C, Gu K, Wang F, Cai H, et al
    Nut consumption in association with overall mortality and recurrence/disease-specific mortality among long-term breast cancer survivors.
    Int J Cancer. 2021 Oct 19. doi: 10.1002/ijc.33824.
    PubMed     Abstract available
    
    
    
65. YE C, Zhou W, Wang F, Yin G, et al
    Prognostic Value of GILT Expression in Female Patients Diagnosed with Breast Cancer.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33843.
    PubMed     Abstract available
    
    
    September 2021
66. ZHANG L, Wu ZY, Li J, Lin Y, et al
    Neoadjuvant Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel in Triple-Negative, Early-Stage Breast Cancer (NeoCART): Results from a Multicenter, Randomized Controlled, Open-Label Phase II Trial.
    Int J Cancer. 2021 Sep 30. doi: 10.1002/ijc.33830.
    PubMed     Abstract available
    
    
    
67. POISEUIL M, Tron L, Woronoff AS, Tretarre B, et al
    How do age and social environment affect the dynamics of death hazard and survival in patients with breast or gynecological cancer in France?
    Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33803.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: